Study design
The WEARCON study had a prospective observational design. After informed consent, children and parents received all study devices, instruction materials, and were instructed at their home. Children were monitored for two weeks at home with wearable devices, followed by an outpatient-clinic visit to assess asthma control (figure 1). This study was approved by the medical ethics committee and was registered in the Netherlands trial register (trial no. NL6087). Oral and written consent to participate were obtained from the parents or legal guardians of the children and from the child itself if he/she was 12 years or older.
Subjects
Sixty children with paediatrician-diagnosed asthma and thirty non-asthmatic children between 4-14 years, were recruited using consecutive sampling.
Asthmatic children (n=60)
The asthmatic children were recruited at the outpatient clinic of the paediatric department of Medisch Spectrum Twente, Enschede, The Netherlands (referral centre for paediatric asthma). Children with paediatrician-diagnosed asthma, who had exercise induced symptoms and were scheduled for an exercise bronchoprovocation test (BPT) between February 2017 and June 2018, were approached to participate in the study. Children with comorbid chronic diseases, children with an inability to understand or speak Dutch, children with electrical stimulation devices (i.e. pacemaker), children with psychomotor retardation, or children for whom it was not possible to wear all wearable devices, i.e. due to severe skin diseases or amputation, were not eligible to participate.
Asthma control was assessed in every child by the same paediatric pulmonologist according to the GINA recommendations of assessment of asthma control (5). Many children with poorly controlled asthma avoid strenuous exercise or mispercept symptoms, so their asthma may appear to be well controlled (5). Therefore, the BPT was used in addition to the GINA recommendations to assess asthma control. Uncontrolled asthma was defined as 1) having an uncontrolled level of asthma symptom control as defined by GINA (three or more of the following conditions in the past 4 weeks; >2 episodes of daytime symptoms weekly, >2 uses of reliever medication weekly, nocturnal symptoms and activity limitation) OR 2) having a positive BPT (>12% decrease in FEV1) (5). The exercise BPT was performed in a climate chamber with dry, cold air (10 degrees Celsius) following the American Thoracic Society protocol (23). Children aged 8–14 years old performed the BPT on a treadmill for 6 minutes with submaximal exercise load (steady-state heart rate of 85% of the maximal heart rate (220 – age)) and their nose clipped. The inclination of the treadmill was 10%. Children aged 4–7 years old performed the exercise on a jumping castle for 6 minutes as described by van Leeuwen et al. (24).
Non-asthmatic children (n=30)
The non-asthmatic controls were recruited with information flyers at schools in the region. The non-asthmatic children received the same medical evaluation to confirm that they did not have asthma. The same exclusion criteria applied for the non-asthmatic group. Children with a prior diagnosis of asthma, prescribed asthma medication or self-reported asthmatic symptoms, were ineligible.
Subject characteristics
Demographic characteristics were retrieved from the electronic patient record. The (C)-ACT score was obtained twice during the 2-week monitoring period after each week of monitoring. Lung function (FEV1 % predicted) and the maximal post-exercise fall in FEV1 were obtained during the BPT.
(Wearable) monitoring devices
Figure 2 shows the four commercially available devices used in the WEARCON study. Our choice of devices was based on the trade-off between 1) the best quality devices (so that the most relevant data could be extracted for this study) and 2) the non-obtrusiveness of the devices, so that it would be feasible for children to be able to use the device for 2 weeks. Physical activity was assessed using the Actigraph WGT3X-BT wireless activity tracker (Actigraph inc. Pensacola, FL). Lung function measurements were performed with the hand-held Spirobank advanced II (MIR inc. Roma, Italy). Medication adherence and reliever medication use were electronically tracked with the Cohero Health smart inhalers. (Cohero inc. New York, NY). Electrocardiography (ECG) was measured using the Emotion Faros 180° (Bittium. Oulu, Findland). Wearables did not show interpretable data to the subjects to prevent any influence and data was stored anonymously.
Data acquisition, preprocessing and analysis
Continuously measured signals had to be at least 75% complete to be eligible for pre-processing and analysis.
Physical activity & sleep:
The subjects wore the activity tracker for fourteen consecutive days in representative school weeks, without (bank) holidays, reflecting the subjects’ average habitual activities (25). The subjects were instructed to attach the tracker at the wrist and remove it only before activities involving water (such as showering or swimming). Physical activity outcome measures yielded the number of minutes spent at each of four activity levels (sedentary, light, moderate and vigorous activity), the average duration (bout length) and the distribution of activities from at least moderate intensity, expressed in the scale parameter of the Weibull distribution (26). Sleep parameters were derived from the activity tracker with the Cole-Kripke sleep algorithm (27). This algorithm provided the average sleep time, wake-up-time (defined in minutes after midnight), sleep efficiency, awake minutes and time per awakening. Furthermore, the sleep restlessness one hour before wake-up was defined as the average vector magnitude activity counts in the hour the children wake-up. All activity and sleep parameters were averaged per day over the two weeks of home-measurement.
Spirometry measurements at home:
Children were instructed to perform spirometry whenever they exercised (before and 3-6 minutes after) and during symptoms (before reliever use). Spirometer flow-volume loops were classified accordingly based on self-reported events (pre-exercise, post-exercise, symptom). Incorrectly blown spirometer measurements were excluded, according to the ATS/ERS criteria for standardisation lung function testing (28). Spirometry outcome measures were the average pre-exercise forced expiratory volume in 1 second (FEV1), pre-exercise forced expiratory flow between 25 and 75% of exhalation (FEF25-75), pre-exercise peak expiratory flow (PEF), the percentage change in FEV1 after exercise and during symptoms and the variation in pre-exercise lung function, defined as the absolute difference between the highest and lowest predicted pre-exercise FEV1.
Smart inhaler:
The date and time of inhalation were acquired from the Cohero Health server. Controller adherence was calculated by dividing the amount of controller medication taken by the amount of medication prescribed (%). Reliever usage was summed for the period of 2 week monitoring.
Heart rate and respiratory rate:
Continuous raw ECG data was acquired for two days and two nights, with at least one vigorous activity within the period (sports, gym class). Subjects were instructed to attach the eMotion Faros device according to the 3-wire lead placement (mid-clavicular under both claviculae and on left abdomen within the rib cage frame). The device was removed before activities involving water.
The raw ECG was pre-processed to retrieve heart rate (HR) and respiratory rate (RR) using ECG-derived respiration, which is known to provide an robust RR estimate (29). Artefact and baseline correction was applied using a FIR filter with a Kaiser window using cut-off frequencies of 0.45 and 39 Hz (30). The RS amplitude was determined by subtracting the S-amplitude from the R-amplitude of the same QRS complex. The respiratory curve based on the RS-amplitude was established by using cubic spline interpolation to construct a respiratory signal with 50 Hz (31). This algorithm was validated against flow measurement on a separate set of subjects during different daily tasks, showing strong positive correlations (r=0.69) and a sensitivity of 91.5% and positive predictive value of 0.998 on assessing single breathing cycles (32).
ECG outcome parameters were the average daytime HR and RR, night-time HR and RR (in beats or breath per minute) and the HR and RR recovery time, defined as the time (seconds) needed to recover to baseline after physical exertion.
Statistical analysis
Descriptive statistics were used to examine all continuous outcome measures and were expressed in means +- standard deviation (SD) for normally distributed variables and with median +- interquartile range (IQR) for not normal distributed variables. Univariate analyses were performed with SPSS statistics (IBM Corp. Released 2013, Version 22.0). Categorical variables were tested with a chi-square test. Homogeneity of variances was verified in all continuous outcome parameters with the Levene’s test. The Shapiro-Wilk test was used to determine whether the variables were normally distributed among all three groups. The variables that did not have a normal distribution were tested with the Kruskal-Wallis test followed by multiple comparisons of Games-Howell. Normally distributed variables were tested with Analysis of Variance (ANOVA) followed by Tukey HSD test for the post-hoc comparisons of the three groups. P-values less than 0.05 were considered as significant.
Prior to the multivariate analysis missing data was handled using the multiple imputation regression method. Missing data patterns were analysed for monotonicity. In case of monotonicity the monotone method was used; in case of random patterns the Markov Chain Monte Carlo method was used. Constraints were added to the variables to prevent unrealistic imputations (e.g. negative lung function values). Five imputed datasets were created and pooled according to the bar procedure (33). Multivariate analysis was performed using a binary logistic regression analysis with asthma control as dependent variable, with the controlled asthma group as reference group. All home monitoring parameters (see table 2) were considered for inclusion in this final multivariate model. Independent variables with a multi-collinearity of more than 0.8 were not both used in the same model. The model was not adjusted for other potential predictors, such as age, gender, allergies etc. Stepwise forward likelihood ratio selection was used as enter method of variables with an entry probability of 0.10 and removal probability of 0.20. The model was optimized using the Nagelkerke pseudo R-squared, so that the model which explained the most of the variation (R2 closest to 1.0) was chosen. The resulting binary logistic regression was used to calculate determine relevant diagnostic validity measures, such as sensitivity, specificity and positive and negative predictive value.
Sample size
WEARCON studied whether asthma control could be accurately assessed using a multiple binary logistic regression model. Agresti and Peduzzi suggested ten cases per event per group (34,35). This indicated that for a three parameter multiple regression model 60 (30/30) asthmatic children, assuming an equal distribution between the children with controlled and uncontrolled asthma (36). Thirty non-asthmatic children were included as well to put all asthma home-monitoring parameters in perspective relative to normal values and opens the opportunity to explore the diagnostic value of these parameters for asthma in general.